Endovascular vs conservative treatment in patients with chronic subdural hematomas and mild symptoms: a study protocol for a multicenter randomized controlled trial (EMBOTRIAL-1)

慢性硬膜下血肿伴轻度症状患者的血管内治疗与保守治疗:一项多中心随机对照试验的研究方案(EMBOTRIAL-1)

阅读:1

Abstract

BACKGROUND: Chronic subdural hematoma (cSDH) is a common neurosurgical condition that is prevalent in elderly patients. There are no well-defined guidelines for cSDH and management strategies vary widely among physicians and institutions, and this variability is expressed in the literature. In general, conservative management is reserved to patients who are asymptomatic or have minor symptoms with mild mass effect. Spontaneous resolution of cSDH is an unusual phenomenon and middle meningeal artery (MMA) embolization seems to reduce the recurrence and progression rate of SDH compared to conventional treatments in multiple cohort studies. A randomized controlled trial is warranted to determine the effectiveness and safety of endovascular embolization for cSDH and whether MMA embolization is superior to conservative management in reducing the progression rate and surgical rescue event. METHODS: This is an Italian multicenter prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE design) to assess the superiority of MMA embolization compared to conservative treatment. A total of 300 patients are planned to be randomized 1:1 to receive MMA embolization (intervention) or conventional treatments (control). The primary outcome is the treatment arm failure which is defined as a composite of incomplete hematoma resolution or surgical rescue within 6 months follow-up. Incomplete hematoma resolution is defined as a reduction of the cSDH thickness ≤50% at follow-up compared to the hematoma thickness measured at the time of randomization. Surgical rescue is intended as hematoma removal for relief or symptoms that developed with continuous growth of the cSDH. In case of bilateral cSDH, the treatment failure occurred when primary outcomes criteria are satisfied for at least one of the two hematomas. DISCUSSION: This multi-centre randomized controlled trial is needed to evaluate the benefit-to-risk ratio of primary embolization of the MMA to facilitate resolution and prevent rescue surgical evacuation of cSDH. If MMA embolization turns out to be superior to conservative management in this trial, this may prompt further confirmatory trials and, at best, may change clinical practice and guideline recommendations. TRIAL REGISTRATION: ClinicalTrials.gov. Identifier: NCT06274580, Registered on 6 February 2024. This protocol was developed in accordance with the SPIRIT Checklist and by use of the structured study protocol template provided by BMC Trials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。